Ascendis Pharma Files 6-K Report
Ticker: ASND · Form: 6-K · Filed: Feb 12, 2025 · CIK: 1612042
Sentiment: neutral
Topics: sec-filing, 6-k, regulatory-update
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K, standard foreign issuer report, no major news.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on February 12, 2025, to report information as a foreign private issuer. The filing indicates that the company is subject to the 1934 Act and will file annual reports under Form 20-F. The company's principal executive offices are located in Hellerup, Denmark.
Why It Matters
This filing is a routine disclosure for foreign private issuers, providing updates on the company's regulatory status and reporting requirements with the SEC.
Risk Assessment
Risk Level: low — This filing is a routine administrative disclosure and does not contain material non-public information that would typically impact stock price.
Key Players & Entities
- Ascendis Pharma A/S (company) — Filer of the 6-K report
- 001-36815 (company) — SEC File Number for Ascendis Pharma A/S
- 20-F (company) — Form under which Ascendis Pharma A/S files annual reports
- Tuborg Boulevard 12 DK-2900 Hellerup Denmark (company) — Principal executive offices address
FAQ
What type of filing is Ascendis Pharma A/S submitting?
Ascendis Pharma A/S is submitting a Form 6-K report.
What is the filing date of this report?
This report was filed on February 12, 2025.
Under which act is this report filed?
This report is filed pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What form does Ascendis Pharma A/S use for its annual reports?
Ascendis Pharma A/S files its annual reports under cover of Form 20-F.
Where are Ascendis Pharma A/S's principal executive offices located?
Ascendis Pharma A/S's principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 15.8 · Accepted 2025-02-12 15:24:09
Key Financial Figures
- $119.51 — y and has an exercise price equal to US $119.51 per share, the closing price of the Ame
Filing Documents
- d937591d6k.htm (6-K) — 13KB
- d937591dex11.htm (EX-1.1) — 1206KB
- g937591dsp174.jpg (GRAPHIC) — 3KB
- g937591dsp175.jpg (GRAPHIC) — 3KB
- g937591dsp177.jpg (GRAPHIC) — 3KB
- g937591dsp178.jpg (GRAPHIC) — 3KB
- g937591dsp179.jpg (GRAPHIC) — 3KB
- g937591dsp180.jpg (GRAPHIC) — 5KB
- g937591dsp_24a.jpg (GRAPHIC) — 4KB
- g937591dsp_25a.jpg (GRAPHIC) — 8KB
- g937591dsp_25b.jpg (GRAPHIC) — 3KB
- g937591dsp_26a.jpg (GRAPHIC) — 6KB
- g937591dsp_33a.jpg (GRAPHIC) — 4KB
- g937591dsp_33b.jpg (GRAPHIC) — 8KB
- g937591dsp_34a.jpg (GRAPHIC) — 3KB
- g937591dsp_34b.jpg (GRAPHIC) — 6KB
- g937591page43.jpg (GRAPHIC) — 4KB
- g937591page44a.jpg (GRAPHIC) — 8KB
- g937591page44b.jpg (GRAPHIC) — 3KB
- g937591page45.jpg (GRAPHIC) — 6KB
- 0001193125-25-025052.txt ( ) — 1340KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: February 12, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer